Last reviewed · How we verify

Cutaneous Tcell lymphoma — Treatment Landscape & Competitive Intelligence

Cutaneous Tcell lymphoma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cutaneous Tcell lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Adcetris brentuximab-vedotin Pfizer CD30-directed Immunoconjugate [EPC] Tubulin beta 2011-01-01
Brentuximab Brentuximab University of Arizona Tumor necrosis factor receptor superfamily member 8, Tubulin beta

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Cutaneous Tcell lymphoma
  2. University of Arizona · 1 drug in Cutaneous Tcell lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cutaneous Tcell lymphoma:

Cite this brief

Drug Landscape (2026). Cutaneous Tcell lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cutaneous-tcell-lymphoma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing